Exelixis, Inc. (EXEL) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $44.88 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CABOMETYX.
Exelixis is an oncology company with two marketed cabozantinib products -- CABOMETYX (RCC, HCC, DTC, pNET/epNET) and COMETRIQ (MTC) -- generating $2.12 billion in net product revenue in 2025. Ex-U.S. commercialization is handled by Ipsen (all markets except Japan) and Takeda... Read more
Sell if holding. Analyst target reached at $44.88 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CABOMETYX. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 6.1/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCABOMETYX10-K Item 1A: 'Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications'
- MEDIUMcounterpartyIpsen10-K Item 1: 'Outside the U.S., we rely on collaboration partners for the commercialization of our cabozantinib products; Ipsen is responsible for all territories outside of the U.S. and Japan'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $44.88 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CABOMETYX. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $42.09. Score 6.1/10, moderate confidence.
Take-profit target: $46.52 (+3.6% upside). Prior stop was $42.09. Stop-loss: $42.09.
Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining; Leverage penalty (D/E 9.3): -1.5.
Exelixis, Inc. trades at a P/E of 16.1 (forward 11.3). TrendMatrix value score: 7.2/10. Verdict: Sell.
27 analysts cover EXEL with a consensus score of 3.7/5. Average price target: $48.
What does Exelixis, Inc. do?Exelixis is an oncology company with two marketed cabozantinib products -- CABOMETYX (RCC, HCC, DTC, pNET/epNET) and...
Exelixis is an oncology company with two marketed cabozantinib products -- CABOMETYX (RCC, HCC, DTC, pNET/epNET) and COMETRIQ (MTC) -- generating $2.12 billion in net product revenue in 2025. Ex-U.S. commercialization is handled by Ipsen (all markets except Japan) and Takeda (Japan); zanzalintinib is in multiple late-stage trials.